NCT04616560 2026-03-19
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
19 trialsNCT05744375 2026-03-12
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT06048718 2026-03-10
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT07069712 2026-03-10
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06486883 2026-03-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07428044 2026-02-23
HERCULES
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07416253 2026-02-18
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06250777 2026-02-09
ELPIS
Yonsei University
Phase 2 Enrolling by invitation
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT04482309 2026-01-21
DPT02
AstraZeneca
Phase 2 Recruiting
NCT04744831 2026-01-14
DESTINY-CRC02
Daiichi Sankyo
Phase 2 Completed
NCT05408845 2026-01-14
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT07340164 2026-01-14
TROY
Yonsei University
Phase 2 Not yet recruiting
NCT07126561 2026-01-08
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
Phase 2 Not yet recruiting